857 related articles for article (PubMed ID: 19010377)
41. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
[TBL] [Abstract][Full Text] [Related]
42. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
43. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
44. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice.
Osman AM; Nemnem MM; Abou-Bakr AA; Nassier OA; Khayyal MT
Food Chem Toxicol; 2009 Oct; 47(10):2425-30. PubMed ID: 19577608
[TBL] [Abstract][Full Text] [Related]
45. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
46. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
[TBL] [Abstract][Full Text] [Related]
48. Strategies for reduction of anthracycline cardiac toxicity.
Speyer J; Wasserheit C
Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
[TBL] [Abstract][Full Text] [Related]
49. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
Thompson KL; Rosenzweig BA; Zhang J; Knapton AD; Honchel R; Lipshultz SE; Retief J; Sistare FD; Herman EH
Cancer Chemother Pharmacol; 2010 Jul; 66(2):303-14. PubMed ID: 19915844
[TBL] [Abstract][Full Text] [Related]
50. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
51. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
52. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
54. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
Gorbsky GJ
Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
[TBL] [Abstract][Full Text] [Related]
55. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
56. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
[TBL] [Abstract][Full Text] [Related]
57. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
58. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
59. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Synold TW; Tetef ML; Doroshow JH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):93-9. PubMed ID: 9768830
[TBL] [Abstract][Full Text] [Related]
60. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
Hershko C; Link G; Tzahor M; Kaltwasser JP; Athias P; Grynberg A; Pinson A
J Lab Clin Med; 1993 Sep; 122(3):245-51. PubMed ID: 8409700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
